Ryoji Gunji

发表

Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world clinical practice: Results of 3‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)

K. Utsunomiya, M. Senda, Seigo Kakiuchi, 2019, Journal of diabetes investigation.

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real‐world practice: Results of 12‐month interim analysis of a long‐term post‐marketing surveillance study (J‐STEP/LT)

K. Utsunomiya, M. Senda, Seigo Kakiuchi, 2019, Journal of diabetes investigation.

Long‐term safety and efficacy of tofogliflozin as add‐on to insulin in patients with type 2 diabetes: Results from a 52‐week, multicentre, randomized, double‐blind, open‐label extension, Phase 4 study in Japan (J‐STEP/INS)

Y. Terauchi, M. Senda, M. Tamura, 2018, Diabetes, obesity & metabolism.

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Y. Terauchi, M. Senda, M. Tamura, 2019, Journal of diabetes investigation.

Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J‐STEP/INS): Results of a 16‐week randomized, double‐blind, placebo‐controlled multicentre trial

Y. Terauchi, M. Senda, M. Tamura, 2017, Diabetes, obesity & metabolism.

Transient intermediate produced from 5-aminouracil in reaction with dichloride anion radical

Ryoji Gunji, K. Yamauchi, T. Masuda, 1983 .

Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study

Ryoji Gunji, H. Tanihara, T. Kanno, 2019, Advances in Therapy.

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post‐marketing study (J‐STEP/EL Study)

K. Utsunomiya, M. Senda, Seigo Kakiuchi, 2017, Journal of diabetes investigation.

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT)

K. Utsunomiya, M. Senda, Seigo Kakiuchi, 2020, Journal of diabetes investigation.

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study)

K. Utsunomiya, M. Senda, Seigo Kakiuchi, 2019, Journal of diabetes investigation.

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT)

K. Utsunomiya, M. Senda, Seigo Kakiuchi, 2020, Journal of diabetes investigation.

Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension: 12-month interim analysis of ROCK-J, a post-marketing surveillance study

Ryoji Gunji, H. Tanihara, T. Kanno, 2020, BMC Ophthalmology.

Effectiveness and safety of an extended‐release tablet of sodium valproate for the prophylactic treatment of migraine: Postmarketing surveillance in Japan

N. Suzuki, T. Takeshima, Yuji Kurihara, 2016, Neurology and clinical neuroscience.

1．The Survey of Trends on Japanese Post-marketing Study after Enforcement of Revised Good Post-marketing Study Practice （GPSP)

Ryoji Gunji, T. Taniguchi, Jiro Hokugo, 2020 .